tiprankstipranks
RBC Capital Reaffirms Their Buy Rating on Avantor (AVTR)
Blurbs

RBC Capital Reaffirms Their Buy Rating on Avantor (AVTR)

In a report released on January 24, Conor McNamara from RBC Capital maintained a Buy rating on Avantor (AVTRResearch Report), with a price target of $28.00. The company’s shares closed yesterday at $22.66.

McNamara covers the Healthcare sector, focusing on stocks such as Illumina, QuidelOrtho, and SOPHiA GENETICS. According to TipRanks, McNamara has an average return of -10.0% and a 38.81% success rate on recommended stocks.

Avantor has an analyst consensus of Strong Buy, with a price target consensus of $24.58, which is an 8.47% upside from current levels. In a report released on January 25, Barclays also maintained a Buy rating on the stock with a $24.00 price target.

See the top stocks recommended by analysts >>

Based on Avantor’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.72 billion and a net profit of $108.4 million. In comparison, last year the company earned a revenue of $1.86 billion and had a net profit of $167 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Avantor (AVTR) Company Description:

Avantor, Inc. is a provider of mission critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. It sells materials & consumables, equipment & instrumentation and services & specialty procurement. It operates in more than 30 countries and deliver an extensive portfolio of products and services. The company was founded by John Townsend Baker in 1904 and is headquartered in Radnor, PA.

Read More on AVTR:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles